Publication: Exenatide increases ctrp3 gene expression in adipose cells by inhibiting adipogenesis and induces apoptosis
dc.contributor.author | Gündüz, Meliha Koldemir | |
dc.contributor.author | Kaymak, Güllü | |
dc.contributor.author | Berikten, Derya | |
dc.contributor.author | Sener, Harun | |
dc.contributor.buuauthor | Kanbur, Ertan | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmunoloji Anabilim Dalı. | |
dc.contributor.orcid | 0000-0001-8399-8942 | |
dc.contributor.researcherid | AAW-6971-2021 | |
dc.date.accessioned | 2024-09-09T10:43:21Z | |
dc.date.available | 2024-09-09T10:43:21Z | |
dc.date.issued | 2022-09-24 | |
dc.description.abstract | Considering the rapidly increasing prevalence of obesity worldwide, the number of weight control drugs is very few. Incretin-based therapies are currently being developed to achieve weight control, and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) are used in incretin-based therapies. This study aimed to investigate the cytotoxicity of exenatide, a GLP-1A, on 3T3-L1 adipocytes and the effect of exenatide on the expression of adipogenesis-related genes, insulin and glucose levels, and apoptosis. Cytotoxic activity of exenatide on 3T3-L1 adipocytes was determined by MTT method. Gene expression levels were determined by qPCR. Apoptosis studies were performed on the Muse Cell Analyzer. C1q/TNF-related protein-3 (CTRP3) expression levels were found to be higher in exenatide treated adipocyte cells than in control cells (p < 0.001). Adipocyte cells treated with exenatide were found to have lower PPAR-gamma gene expression levels when compared to control adipocyte cells (p < 0.001). Intracellular insulin (p < 0.001) and glucose levels were higher in 3T3-L1 adipocytes treated with exenatide compared to control adipocyte cells. Total apoptosis increased approximately 1.5 times as a result of exenatide administration. The increase in CTRP3 gene expression, which is thought to be a new biomarker for obesity, and the decrease in PPAR-gamma gene expression indicate that exenatide is a promising new pharmaco-therapeutic agent in the treatment of obesity by regulating the expression of genes related to adipogenesis and lipogenesis and inducing apoptosis. | |
dc.description.sponsorship | Scientific Research Projects Coordination Unit of Kütahya Health Sciences University TSA-2021-56 | |
dc.identifier.doi | 10.1016/j.tiv.2022.105479 | |
dc.identifier.issn | 0887-2333 | |
dc.identifier.uri | https://doi.org/10.1016/j.tiv.2022.105479 | |
dc.identifier.uri | https://hdl.handle.net/11452/44399 | |
dc.identifier.volume | 85 | |
dc.identifier.wos | 000865440000001 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Pergamon-elsevier Science Ltd | |
dc.relation.journal | Toxicology In Vitro | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Glucagon-like peptide-1 | |
dc.subject | C1q/tnf-related protein-3 ctrp3 | |
dc.subject | Type-2 diabetes-mellitus | |
dc.subject | Adaptive thermogenesis | |
dc.subject | Arterial stiffness | |
dc.subject | Gamma agonist | |
dc.subject | Ppar-gamma | |
dc.subject | Tissue | |
dc.subject | Glp-1 | |
dc.subject | Adipocytes | |
dc.subject | Obesity | |
dc.subject | Adipogenesis | |
dc.subject | 3t3-l1 cell line | |
dc.subject | Exenatide | |
dc.subject | Ctrp3 gene | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Toxicology | |
dc.title | Exenatide increases ctrp3 gene expression in adipose cells by inhibiting adipogenesis and induces apoptosis | |
dc.type | Article | |
dspace.entity.type | Publication |